Sun Pharma presents early data on GLP-1 drug Utreglutide in US
This story was originally published at 17:09 IST on 12 November 2025
Register to read our real-time news.Informist, Wednesday, Nov. 12, 2025
HYDERABAD — Sun Pharmaceutical Industries Ltd. showcased early results from Phase- 1b and Phase-2a studies of its investigational glucagon-like peptide-1, or GLP-1, receptor agonist utreglutide, code-named GL0034, at Obesity Week 2025 in Atlanta, the US, the company said in a press release.
In one study conducted in Australia, once-weekly Utreglutide treatment in individuals with class-III obesity and Metabolic Dysfunction-associated Steatotic Liver Disease led to notable body weight and waist circumference reduction, improved cardio-metabolic markers, and significant liver fat loss in 31% of subjects. The therapy was well tolerated, with nausea, diarrhoea, and vomiting being the most common adverse events.
In a separate 10-week study conducted in Belgium, Utreglutide demonstrated a 6.8% reduction in body weight, improvements in lipid parameters including a 10% drop in total and LDL cholesterol, the company said.
These results suggest Utreglutide has the potential to address obesity-related metabolic disorders and cardiovascular risks, with or without diabetes. Utreglutide is discovered and developed by Sun Pharma, continues to advance through clinical studies for its safety and efficacy in obesity and type-2 diabetes, the company said.
On Wednesday, Sun Pharmaceutical Industries shares ended at INR 1,732.10 on the National Stock Exchange, up nearly 1% from its previous close. End
Reported by Narayana Krishna
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
